Education
About Us
Working with TipRanks
Follow Us
NeurAxis, Inc. (NRXS)
:NRXS
NRXS Stock Chart & Stats
$6.86
-$0.04(-1.54%)
At close: 4:00 PM EST
$6.86
-$0.04(-1.54%)
Day’s Range― - ―
52-Week Range$1.33 - $7.43
Previous CloseN/A
Volume9.85K
Average Volume (3M)55.04K
Market Cap
$73.08M
Enterprise Value$69.18M
Total Cash (Recent Filing)$4.38M
Total Debt (Recent Filing)$478.43K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Mar 19, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding10,652,812
10 Day Avg. Volume34,967
30 Day Avg. Volume55,039
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)7.86
Price to Sales (P/S)6.05
P/FCF Ratio-2.65
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue20.57
Enterprise Value/Gross Profit24.40
Enterprise Value/Ebitda-9.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$8.50M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsSustained ~84% gross margins indicate durable pricing power and low variable cost for device sales and consumables. This margin cushion supports reinvestment in commercialization and R&D as adoption scales, reducing the capital needed per incremental dollar of revenue.
FDA Indication ExpansionRegulatory expansion into functional abdominal pain and dyspepsia broadens the addressable market across pediatric and adult patients. Durable clinical indications increase long-term adoption by providers and strengthen reimbursement arguments, supporting sustained revenue growth over multiple years.
Reimbursement Catalyst & Payer EngagementA Category One CPT code plus active payer engagement is a structural market-access catalyst that can materially expand covered lives and utilization. Durable improvement in reimbursement would reduce adoption friction, enabling scalable commercial uptake and more predictable revenue streams.
Bears Say
Ongoing Cash BurnConsistent negative operating and free cash flow signals reliance on external financing to fund operations. Over the medium term this constrains strategic flexibility, raises dilution or refinancing risk, and pressures the timeline to achieve breakeven as commercialization investments continue.
Deep UnprofitabilityVery large operating and net losses indicate the business is not yet self-sustaining; returns on equity remain deeply negative. Persistent unprofitability limits internal capital for growth, increases sensitivity to funding markets, and raises execution risk until margins normalize with scale.
Reimbursement UncertaintyAbsent broad national coverage today, payer uncertainty constrains addressable market and adoption cadence. Even with a future CPT code, timing and policy adoption vary by payer; prolonged coverage gaps could delay commercialization, constrain revenue realization and prolong cash burn.
NeurAxis, Inc. News
NRXS FAQ
What was NeurAxis, Inc.’s price range in the past 12 months?
NeurAxis, Inc. lowest stock price was $1.33 and its highest was $7.43 in the past 12 months.
What is NeurAxis, Inc.’s market cap?
NeurAxis, Inc.’s market cap is $73.08M.
When is NeurAxis, Inc.’s upcoming earnings report date?
NeurAxis, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 4 days.
How were NeurAxis, Inc.’s earnings last quarter?
NeurAxis, Inc. released its earnings results on Nov 11, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.04.
Is NeurAxis, Inc. overvalued?
According to Wall Street analysts NeurAxis, Inc.’s price is currently Overvalued.
Does NeurAxis, Inc. pay dividends?
NeurAxis, Inc. does not currently pay dividends.
What is NeurAxis, Inc.’s EPS estimate?
NeurAxis, Inc.’s EPS estimate is -0.22.
How many shares outstanding does NeurAxis, Inc. have?
NeurAxis, Inc. has 10,652,812 shares outstanding.
What happened to NeurAxis, Inc.’s price movement after its last earnings report?
NeurAxis, Inc. reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went down -5.859%.
Which hedge fund is a major shareholder of NeurAxis, Inc.?
Currently, no hedge funds are holding shares in NRXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeurAxis, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.07%
12-Months-Change
Fundamentals
Return on Equity
-3071.15%
Trailing 12-Months
Asset Growth
405.25%
Trailing 12-Months
Company Description
NeurAxis, Inc.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
NRXS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and successful milestones, including FDA indication expansions and strategic payer engagement. However, challenges remain with reimbursement, operating expenses, and uncertainty around the RED device. The sentiment is bolstered by strategic planning for 2026 with the new CPT code, but tempered by ongoing financial and market access challenges.View all NRXS earnings summariesNRXS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
IGC Pharma
―
Minerva Neurosciences
―
Passage Bio
―
Liminatus Pharma
―
Klotho Neurosciences
―
Ownership Overview
10.70% Insiders
0.91% Mutual Funds
11.33% Other Institutional Investors
75.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---